Effectiveness of ivermectin-based multidrug therapy in severely hypoxic, ambulatory COVID-19 patients.

IF 2.5 4区生物学 Q3 MICROBIOLOGY

Future microbiology Pub Date : 2022-03-01 Epub Date: 2022-02-09 DOI:10.2217/fmb-2022-0014

Sabine Hazan, Sonya Dave, Anoja W Gunaratne, Sibasish Dolai, Robert L Clancy, Peter A McCullough, Thomas J Borody

{"title":"Effectiveness of ivermectin-based multidrug therapy in severely hypoxic, ambulatory COVID-19 patients.","authors":"Sabine Hazan, Sonya Dave, Anoja W Gunaratne, Sibasish Dolai, Robert L Clancy, Peter A McCullough, Thomas J Borody","doi":"10.2217/fmb-2022-0014","DOIUrl":null,"url":null,"abstract":"Aims: Ivermectin is a safe, inexpensive and effective early COVID-19 treatment validated in 20+ random, controlled trials. Having developed combination therapies for Helicobacter pylori, the authors present a highly effective COVID-19 therapeutic combination, stemming from clinical observations. Patients & methods: In 24 COVID-19 subjects refusing hospitalization with high-risk features, hypoxia and untreated moderate to severe symptoms averaging 9 days, the authors administered this novel combination of ivermectin, doxycycline, zinc and vitamins D and C. Results & conclusions: All subjects resolved symptoms (in 11 days on average), and oxygen saturation improved in 24 h (87.4% to 93.1%; p = 0.001). There were no hospitalizations or deaths, less than (p < 0.002 or 0.05, respectively) background-matched CDC database controls. Triple combination therapy is safe and effective even when used in outpatients with moderate to severe symptoms. Clinical Trial Registration: NCT04482686 (ClinicalTrial.gov).","PeriodicalId":12773,"journal":{"name":"Future microbiology","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8826831/pdf/","citationCount":"21","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future microbiology","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.2217/fmb-2022-0014","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/2/9 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MICROBIOLOGY","Score":null,"Total":0}

引用次数: 21

Abstract

Aims: Ivermectin is a safe, inexpensive and effective early COVID-19 treatment validated in 20+ random, controlled trials. Having developed combination therapies for Helicobacter pylori, the authors present a highly effective COVID-19 therapeutic combination, stemming from clinical observations. Patients & methods: In 24 COVID-19 subjects refusing hospitalization with high-risk features, hypoxia and untreated moderate to severe symptoms averaging 9 days, the authors administered this novel combination of ivermectin, doxycycline, zinc and vitamins D and C. Results & conclusions: All subjects resolved symptoms (in 11 days on average), and oxygen saturation improved in 24 h (87.4% to 93.1%; p = 0.001). There were no hospitalizations or deaths, less than (p < 0.002 or 0.05, respectively) background-matched CDC database controls. Triple combination therapy is safe and effective even when used in outpatients with moderate to severe symptoms. Clinical Trial Registration: NCT04482686 (ClinicalTrial.gov).

Abstract Image

查看原文本刊更多论文

以伊维菌素为基础的多药治疗重症缺氧门诊COVID-19患者的疗效观察

目的:伊维菌素是一种安全、廉价和有效的早期COVID-19治疗方法，在20多个随机对照试验中得到验证。在开发了针对幽门螺杆菌的联合疗法之后，作者根据临床观察提出了一种高效的COVID-19治疗组合。患者和方法:对24例具有高危特征、缺氧且未治疗的平均9天中重度症状的COVID-19患者，作者给予伊维菌素、多西环素、锌和维生素D和c的新型联合治疗。结果与结论:所有患者症状均缓解(平均11天)，24 h血氧饱和度改善(87.4% ~ 93.1%);p = 0.001)。临床试验注册:NCT04482686 (ClinicalTrial.gov)。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future microbiology 生物-微生物学

CiteScore

4.90

自引率

3.20%

发文量

134

审稿时长

6-12 weeks

期刊介绍： Future Microbiology delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this increasingly important and vast area of research.